Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients

Table 4 Association between ABCG2 polymorphism and clinical outcome of tyrosine kinase inhibitions (TKIs) therapy in 70 NSCLC patients

	Clinical outcome		P -value	PFS (95% CI)	P -value	OS (95% CI)	P -value
	Sensitive (n)	Resistive (n)	P -value	PFS (95% CI)	P -value	OS (95% CI)	P -value
34 G/A
GG	15	10		6.5 (4.1-8.9)		18 (14.9-21.1)
GA + AA	31	14	0.453	8.0 (5.9-10.1)	0.355	31 (22.9-39.1)	0.005
421 C/A
CC	22	13		7.0 (3.7-10.4)		19 (7.4-30.6)
CA + AA	24	11	0.615	8.0 (6.1-9.9)	0.089	28 (15.0-41.0)	0.823
1143 C/T
CC	32	16		8.0 (5.4-10.7)		21 (11.0-30.0)
CT + TT	14	8	0.804	6.5 (3.12-9.8)	0.082	27.5 (15.4-39.6)	0.872

PFS: progression-free survival; OS: overall survival; 95% CI: 95% confidence intervals.

ISSN: 1475-2867